User: Guest  Login
Title:

Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction.

Document type:
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
Author(s):
Ferreira, João Pedro; Butler, Javed; Zannad, Faiez; Filippatos, Gerasimos; Schueler, Elke; Steubl, Dominik; Zeller, Cordula; Januzzi, James L; Pocock, Stuart; Packer, Milton; Anker, Stefan D
Abstract:
BACKGROUND: Mineralocorticoid receptor antagonists (MRAs) may be beneficial in reducing heart failure (HF) hospitalizations in patients with HF with preserved ejection fraction. The effect of sodium-glucose cotransporter 2 inhibitors in patients with HF with preserved ejection fraction according to MRA background therapy has not been reported. OBJECTIVES: The aim of this study was to examine the effect of empagliflozin in MRA users and nonusers in the EMPEROR-Preserved (Empagliflozin Outcome Tri...     »
Journal title abbreviation:
J Am Coll Cardiol
Year:
2022
Journal volume:
79
Journal issue:
12
Pages contribution:
1129-1137
Fulltext / DOI:
doi:10.1016/j.jacc.2022.01.029
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/35331406
Print-ISSN:
0735-1097
TUM Institution:
Professur für Nephrologie (Prof. Heemann)
 BibTeX